GlassScriptPhysician profile
Karen A Kinney
NPI 1760474175
$2,717.33
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $754 · 2021: $1,186 · 2022: $152.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $451.79 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $405.25 | 2019-2022 | |
| Allergan, INC. | $304.77 | 2019-2020 | |
| Alkermes, INC. | $300.60 | 2019-2022 | |
| Abbvie INC. | $248.48 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $227.98 | 2019-2021 | |
| Lundbeck LLC | $166.54 | 2020-2021 | |
| Indivior INC. | $153.09 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.21 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $120.13 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $88.74 | 2019-2022 | |
| Eisai INC. | $76.26 | 2020-2021 | |
| Shire North American Group INC | $33.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.78 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Kinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.